PMID- 24586701
OWN - NLM
STAT- MEDLINE
DCOM- 20150127
LR  - 20211021
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 2
DP  - 2014
TI  - Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic 
      fibrosis.
PG  - e89341
LID - 10.1371/journal.pone.0089341 [doi]
LID - e89341
AB  - BACKGROUND: One in four cystic fibrosis (CF) patients diagnosed with a pulmonary 
      exacerbation will not recover their baseline lung function despite standard 
      treatment. This highlights the importance of preventing such events. Clinical 
      decision-making can be improved through a simple blood test that predicts 
      individuals at elevated short-term risk of an exacerbation. METHODS: We obtained 
      plasma samples from 30 stable CF patients from the St. Paul's Hospital Adult CF 
      Clinic (Vancouver, Canada). For 15 patients, an additional plasma sample was 
      obtained during an exacerbation. Soluble CD14 (sCD14) and C-reactive protein 
      (CRP) were quantified using ELISA kits. Myeloperoxidase (MPO), interleukin(IL)-6, 
      IL-1beta, monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth 
      factor (VEGF), and granulocyte colony-stimulating factor (G-CSF) were quantified 
      using Luminex immunoassays. Stable state biomarker levels were examined in their 
      ability to predict individuals that would experience a pulmonary exacerbation 
      requiring intravenous (IV) antibiotics within 4 months. Paired stable and 
      exacerbation plasma biomarker levels were also compared. RESULTS: sCD14 levels 
      were significantly higher in patients that experienced a pulmonary exacerbation 
      requiring IV antibiotics within 4 months (p = 0.001). sCD14 cut-off value of 1450 
      ng/mL was associated with an area under the curve of 0.91 (95% CI 0.83-0.99) for 
      predicting an exacerbation within 4 months of a stable visit, with a sensitivity 
      of 100% and specificity of 82%. Plasma sCD14 levels were significantly higher 
      during exacerbations than during periods of clinical stability (p = 0.03). 
      CONCLUSIONS: Plasma sCD14 is a promising biomarker for identifying CF patients 
      who will exacerbate within 4 months of a stable visit but requires further study 
      in larger, independent cohorts.
FAU - Quon, Bradley S
AU  - Quon BS
AD  - Centre for Heart Lung Innovation, St. Paul's Hospital, University of British 
      Columbia, Vancouver, British Columbia, Canada ; Division of Respiratory Medicine, 
      St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, 
      Canada.
FAU - Ngan, David A
AU  - Ngan DA
AD  - Centre for Heart Lung Innovation, St. Paul's Hospital, University of British 
      Columbia, Vancouver, British Columbia, Canada.
FAU - Wilcox, Pearce G
AU  - Wilcox PG
AD  - Centre for Heart Lung Innovation, St. Paul's Hospital, University of British 
      Columbia, Vancouver, British Columbia, Canada ; Division of Respiratory Medicine, 
      St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, 
      Canada.
FAU - Man, S F Paul
AU  - Man SF
AD  - Centre for Heart Lung Innovation, St. Paul's Hospital, University of British 
      Columbia, Vancouver, British Columbia, Canada ; Division of Respiratory Medicine, 
      St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, 
      Canada.
FAU - Sin, Don D
AU  - Sin DD
AD  - Centre for Heart Lung Innovation, St. Paul's Hospital, University of British 
      Columbia, Vancouver, British Columbia, Canada ; Division of Respiratory Medicine, 
      St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140220
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 0 (Lipopolysaccharide Receptors)
SB  - IM
MH  - Adult
MH  - Biomarkers/*blood
MH  - Cystic Fibrosis/*blood/*diagnosis
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Lipopolysaccharide Receptors/*blood
MH  - Male
MH  - Prognosis
MH  - Respiratory Function Tests
MH  - Young Adult
PMC - PMC3930718
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/03/04 06:00
MHDA- 2015/01/28 06:00
PMCR- 2014/02/20
CRDT- 2014/03/04 06:00
PHST- 2013/11/01 00:00 [received]
PHST- 2014/01/19 00:00 [accepted]
PHST- 2014/03/04 06:00 [entrez]
PHST- 2014/03/04 06:00 [pubmed]
PHST- 2015/01/28 06:00 [medline]
PHST- 2014/02/20 00:00 [pmc-release]
AID - PONE-D-13-44888 [pii]
AID - 10.1371/journal.pone.0089341 [doi]
PST - epublish
SO  - PLoS One. 2014 Feb 20;9(2):e89341. doi: 10.1371/journal.pone.0089341. eCollection 
      2014.